SequelSEC

Aspira Women's Health Inc. AWHL

In Vitro & In Vivo Diagnostic Substances · CIK 0000926617 · Fiscal year ends 1231

Revenue
$343.00K
Fiscal year ended 2025-12-31
Operating income
-$7.91M
Fiscal year ended 2025-12-31
Free cash flow
-$7.04M
Fiscal year ended 2025-12-31

Aspira Women's Health Inc. (AWHL) reported revenue of $343.00K and net income of -$12.78M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aspira Women's Health Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

Aspira Women's Health Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$343.00K$4.00K$87.00M$8.18M$6.81M$4.65M$4.54M$3.05M$3.12M$2.64M
Cost of revenueUnavailableUnavailableUnavailable$3.86M$3.75M$3.42M$3.34M$3.14M$2.91M$2.70M
Gross profitUnavailableUnavailableUnavailable$4.32M$3.06M$1.24M$1.20M-$89.00K$207.00K-$56.00K
Operating income-$7.91M-$16.28M-$18.85M-$31.14M-$32.60M-$17.98M-$15.28M-$11.33M-$10.44M-$14.95M
Net income-$12.78M-$13.09M-$16.69M-$29.88M-$31.66M-$17.90M-$15.24M-$11.37M-$10.50M-$14.97M
Research & development$2.88M$3.27M$4.04M$5.92M$5.31M$2.10M$1.02M$550.00K$837.00K$2.17M
Weighted-average diluted sharesshares 34.10Mshares 14.13Mshares 9.23Mshares 7.77Mshares 7.41Mshares 100.72Mshares 86.60Mshares 70.09Mshares 56.94Mshares 52.20M
Pretax income-$12.78M-$13.09M$16.69M$29.90M$31.66M$17.90M$15.24MUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$0$0
Diluted EPS$-0.37$-0.93$-1.81$-3.85$-4.27$-0.18$-0.18$-0.16$-0.20$-0.29
Selling, general & administrative$10.95M$18.49M$20.08M$29.54M$30.34M$17.11M$15.46M$10.69M$9.81M$12.73M
General & administrative$7.96M$10.34M$12.27M$14.63M$13.26M$8.27M$5.81M$5.05M$5.54M$5.93M
Selling & marketing$2.99M$8.15M$7.81M$14.92M$17.09M$8.84M$9.64M$5.64M$4.27M$6.80M

Balance

Aspira Women's Health Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$1.76M$1.77M$2.60M$13.31M$37.18M$16.63MUnavailableUnavailable$5.54M$5.24M
Total assets$5.46M$5.49M$6.26M$17.37M$41.08M$19.60M$13.83M$11.41M$7.50M$8.02M
Current assets$4.06M$4.18M$5.28M$16.31M$40.00M$18.60M$13.41M$10.79M$6.30M$6.11M
Total liabilities$12.39M$8.05M$8.63M$10.39M$10.91M$9.89M$5.09M$4.26M$4.09M$4.26M
Current liabilities$3.46M$5.47M$5.12M$5.53M$7.84M$6.00M$3.98M$2.96M$2.61M$2.56M
Total equity incl. NCI-$6.93M-$2.56M-$2.36M$6.98M$30.17M$9.72M$8.74M$7.15M$3.41M$3.76M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$256.00K$326.00K$227.00K$316.00K$174.00K$30.00K$25.00K$92.00K$102.00K$93.00K
Accounts receivable$1.21M$990.00K$1.46M$1.24M$1.03M$865.00K$924.00K$786.00K$205.00K$275.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$1.04M$1.28M$1.43M$2.32M$2.72M$3.48M$1.10M$1.29M$1.48M$1.67M
Accounts payable$1.24M$2.17M$1.26M$881.00K$1.50M$1.10M$855.00K$950.00K$745.00K$881.00K

Cash flow

Aspira Women's Health Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$7.03M-$12.11M-$15.89M-$31.07M-$27.40M-$14.73M-$12.96M-$9.37M-$8.13MUnavailable
Capital expenditures$16.00K$37.00K$24.00K$232.00K$184.00K$490.00K$133.00K$113.00K$60.00K$1.26M
Investing cash flow-$401.00K-$37.00K-$24.00K-$232.00K-$184.00K-$490.00K-$133.00K-$113.00K-$60.00KUnavailable
Financing cash flow$7.42M$11.06M$5.22M$7.43M$48.38M$20.15M$15.44M$13.30M$8.49MUnavailable
Net change in cash-$14.00K-$1.09M-$10.70M-$23.87M$20.80M$4.93M$2.34M$3.82M$297.00K-$13.40M
Stock-based compensation$531.00K$1.49M$1.72M$2.41M$3.54M$1.55M$1.19M$1.10M$1.44M$1.18M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$112.00K$92.00K$199.00K$264.00K$302.00K$265.00K$333.00K$675.00K$786.00K$723.00K

Derived

Aspira Women's Health Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$7.04M-$12.15M-$15.92M-$31.30M-$27.58M-$15.22M-$13.10M-$9.48M-$8.19MUnavailable
Gross margin1724.5%136975.0%6.0%52.8%45.0%26.6%26.3%-2.9%6.6%-2.1%
Operating margin-2307.0%-406950.0%-21.7%-380.5%-478.5%-386.6%-336.7%-371.2%-334.5%-566.0%
FCF margin-2053.9%-303750.0%-18.3%-382.5%-404.9%-327.3%-288.6%-310.5%-262.4%Unavailable
SBC / revenue154.8%37350.0%2.0%29.5%52.0%33.3%26.3%36.1%46.1%44.6%
Current ratio1.17x0.76x1.03x2.95x5.10x3.10x3.37x3.64x2.42x2.39x
Revenue YoY growth8475.0%-100.0%963.0%20.1%46.5%2.5%48.6%-2.2%18.1%Unavailable
Net margin-3725.9%-327350.0%-19.2%-365.2%-464.8%-385.0%-335.8%-372.5%-336.3%-566.5%
R&D / revenue839.1%81650.0%4.6%72.3%78.0%45.2%22.4%18.0%26.8%82.2%
CapEx / revenue4.7%925.0%0.0%2.8%2.7%10.5%2.9%3.7%1.9%47.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AWHL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-19View SEC filing

Companies in the same industry

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.